Victoza for weight loss: what one year of liraglutide actually does

What did @gwen.in.doubt actually say?

Gwen says she has been on Victoza (liraglutide) for one year, currently weighing 158 pounds and targeting 155. She reports her A1C dropped from a prediabetic starting point to 6.1, just 0.1 percentage points lower than when she started. Her doctor recently bumped her dose to 2.0 or 2.4 mg, after eight months at 1.8 mg. She mentions nausea from the dose increase and frames the medication as both a weight management and metabolic tool, not purely cosmetic.

Credit where it is due: she is unusually transparent. She names her current weight, her A1C number, her dose, and her timeline. That is more clinical specificity than most GLP-1 content on TikTok, where before-and-after visuals do all the talking and the numbers stay conveniently vague.

Does the science back this up?

Mostly, yes. The SCALE Obesity and Prediabetes trial (le Roux et al., 2017, The Lancet) followed over 2,000 adults with overweight or obesity and prediabetes for three years on liraglutide 3.0 mg. The liraglutide group lost an average of about 6.1% body weight versus 1.9% in placebo. Gwen is describing results broadly consistent with that evidence base.

Her A1C trajectory is also realistic. The SCALE trial showed meaningful reductions in progression to type 2 diabetes, and modest but real A1C improvements in people starting in the prediabetic range. Dropping from roughly 6.2 to 6.1 after one year is not dramatic, but it is not unusual either, particularly if her weight loss has plateaued. The medication is not a linear A1C eraser. Diet, activity, and how much weight is actually lost all shape the glycemic response significantly.

What did they get wrong (or right)?

She got the framing right. Describing Victoza as a dual-purpose tool for weight and metabolic health is accurate. Liraglutide is FDA-approved for both type 2 diabetes management and chronic weight management, and using it specifically to address prediabetes and obesity simultaneously reflects legitimate clinical practice.

One gap worth naming: she says her A1C is only 0.1% lower than when she started, which means it moved from approximately 6.2 to 6.1. That is a disappointingly small A1C shift after a full year. She does not examine why. Possible explanations include her starting dose being conservative for most of that period, dietary patterns, or the fact that weight loss alone drives much of the glycemic benefit. If weight has plateaued, A1C often plateaues too. She presents this number without that context, which could mislead viewers into thinking modest A1C movement is normal and acceptable without further action.

She also says she gets to decide when to go up or down on her dose, which somewhat undersells the role of clinical oversight. Dose titration on GLP-1 receptor agonists should be guided by a prescriber based on tolerability and response, not solely patient preference.

What should you actually know?

Victoza (liraglutide) is not the same drug as Ozempic (semaglutide), despite both being GLP-1 receptor agonists. Gwen acknowledges the Ozempic confusion directly, which is good. The mechanisms overlap, but the molecules, dosing schedules, and clinical trial data are distinct. Liraglutide is a daily injection. Semaglutide is weekly. The STEP trials for semaglutide showed larger average weight loss than the SCALE trials for liraglutide. They are not interchangeable.

For anyone watching this as a roadmap: a 6.1 A1C after one year on a GLP-1 is not a failure, but it is a conversation your prescriber needs to be part of. The target of 5.7 or below that Gwen mentions is clinically reasonable for reversing prediabetes, and research does show that goal is achievable with sufficient weight loss and lifestyle changes alongside medication. But getting there usually requires more than medication adjustment alone.

• Liraglutide is dosed daily, unlike weekly semaglutide or tirzepatide options
• A1C improvement on GLP-1s is closely tied to actual weight lost, not just time on medication
• Nausea after a dose increase is well-documented and typically transient, but worsening GI symptoms should be reported to a prescriber